Covalon Technologies Highlights Compassionate Care Technologies at 2024 ANCC National Magnet Conference
30 Outubro 2024 - 4:09PM
Business Wire
Visit Covalon at booth 562 to discover the
latest in vascular access innovation.
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV:
COV; OTCQX: CVALF), is pleased to announce its participation in the
American Nurses Credentialing Center (“ANCC”) National Magnet
Conference® from Wednesday, October 30 to Saturday, November 1,
2024, in New Orleans, LA.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20241030398159/en/
(Photo: Business Wire)
The ANCC National Magnet Conference® is a premier event for
nurses seeking to align with ANCC standards, build valuable
connections with nursing leaders and peers, and explore the latest
trends with global nursing experts. Covalon will be showcasing its
innovative vascular access solutions at Booth 562, demonstrating
how they can help support nurses in providing high-quality patient
care.
“We’re excited to join the 2024 Magnet Conference and connect
with nurses from across the country,” said Ron Hebert, Senior Vice
President of Growth at Covalon. “Our gentle-to-skin silicone
adhesive IV securement dressings and vascular access line guards
reflect our belief that compassionate care starts with technology
that can help protect every patient. This commitment aligns with
the conference’s mission to provide nurses with tools and
educational opportunities that drive nursing excellence. We look
forward to sharing our latest innovations with attendees, as well
as the opportunity to learn from the remarkable speakers and
attendees at this event.”
At the Covalon booth, nurses can:
- Learn about the company’s latest vascular access products to
help improve patient comfort.
- See live demonstrations of Covalon’s medical products.
- Network with Covalon representatives and other health care
professionals.
Covalon’s patented vascular access products include:
- VALGuard®: Transparent vascular access line guard designed to
protect IV line connections and hubs from external contaminants,
including body fluids and other secretions.
- IV Clear®: Dual antimicrobial clear silicone adhesive IV
securement dressing with chlorhexidine and silver that provides
antimicrobial protection throughout the entire dressing surface
area.
- CovaClear® IV: Clear soft silicone adhesive IV dressing that
helps protect insertion sites from external contaminants. Suitable
for patients who either don’t require, or cannot tolerate,
antimicrobials.
- SurgiClear®: Dual antimicrobial clear silicone adhesive
dressing with chlorhexidine and silver used to cover and protect
wound sites and wound closure devices.
Scheduling Appointments and Additional Information
To book an appointment with a Covalon representative, please
email Ron Hebert, SVP Growth, Covalon Technologies Ltd., at
rhebert@covalon.com.
Conference Details
- Dates: October 30 – November 1, 2024
- Location: New Orleans Ernest N. Morial Convention Center, 900
Convention Center Blvd., New Orleans, Louisiana 70130
- Registration:
https://magnetpathwaycon.nursingworld.org/conference-registration
For healthcare providers unable to attend the conference,
Covalon encourages you to visit www.covalon.com or follow the
company on LinkedIn, Facebook, or Instagram to learn more about its
solutions.
About Covalon
Covalon is a patient-driven medical device company, that
provides innovative and cost-effective healthcare solutions for
advanced wound care, infection control, and medical device
coatings. Through a strong portfolio of patented technologies and
solutions, we offer innovative, gentle and more compassionate
options to aid patients on their healing journey. Our solutions are
designed for patients and made for care providers. Covalon
leverages its patented medical technology platforms and expertise
in two ways: (i) by developing products that are sold under
Covalon’s name; and (ii) by developing and commercializing medical
products for other medical companies under development and license
contracts. The Company is listed on the TSX Venture Exchange,
having the symbol COV and trades on the OTCQX Market under the
symbol CVALF. To learn more about Covalon, visit our website at
www.covalon.com.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
This news release may contain forward-looking statements which
reflect the Company's current expectations regarding future events.
The forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate", "plan,
"estimate", "expect", "intend", or variations of such words and
phrases or state that certain actions, events, or results “may”,
“could”, “would”, “might”, “will” or “will be taken”, “occur”, or
“be achieved”. In addition, any statements that refer to
expectations, projections or other characterizations of future
events or circumstances contain forward-looking information.
Statements containing forward-looking information are not
historical facts, but instead represent management’s expectations,
estimates, and projections regarding future events. Forward-looking
statements involve risks and uncertainties, including, but not
limited to, the factors described in greater detail in the “Risks
and Uncertainties” section of our management’s discussion and
analysis of financial condition and results of operations for the
year ended September 30, 2023, which is available on the Company’s
profile at www.sedarplus.ca, any of which could cause results,
performance, or achievements to differ materially from the results
discussed or implied in the forward-looking statements. Investors
should not place undue reliance on any forward-looking statements.
The forward-looking statements contained in this news release are
made as of the date of this news release, and the Company assumes
no obligation to update or alter any forward-looking statements,
whether as a result of new information, further events, or
otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241030398159/en/
To learn more about Covalon, please contact: Investor Relations,
Covalon Technologies Ltd. Email: investors@covalon.com Website:
https://covalon.com/
Covalon Technologies (TSXV:COV)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Covalon Technologies (TSXV:COV)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024